Company Overview of REGiMMUNE Corporation
REGiMMUNE Corporation, a biotechnology company, engages in the discovery, development, and commercialization of immune-regulatory therapeutics to treat life-threatening diseases and disorders. It offers therapeutics for allergies, autoimmune diseases, and transplantation disorders. The company’s products include RGI-2001, a drug in the class of Treg-inducing agents; RGI-1000 for allergy; and RGI-3100 series for type 1 diabetes, as well as products for preventing inhibitor formation in enzyme replacement therapies and for IBD. The company was founded in 2006 and is headquartered in Tokyo, Japan with an additional office in San Francisco, California.
35-3 Hakozaki-cho 5F
Founded in 2006
Key Executives for REGiMMUNE Corporation
President, CEO & Director
Chief Development Officer and Senior Director
Compensation as of Fiscal Year 2017.
REGiMMUNE Corporation Key Developments
REGiMMUNE Corporation Announces Publication Phase IIa Hematopoietic Cell Transplantation Results
Mar 9 17
REGiMMUNE Corporation announced the publication of its Phase IIa clinical trial results for RGI-2001, a novel liposomal formulation of a synthetic derivative of alpha-galactosylceramide, to ameliorate graft versus host disease (GvHD) after allogeneic hematopoietic cell transplantation. RGI-2001 is a naturally occurring ligand that binds to CD1d and activates invariant natural killer T cells (iNKT). The company is developing RGI-2001 The paper: Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells is now available from the online publication Biology of Blood and Marrow Transplantation. This is the first clinical demonstration of a novel therapeutic that potentially expands Foxp3+regulatory T cells (Treg) mediated by the activation of iNKT cells in patients. RGI-2001, which utilizes the company's reVax technology, promotes transplantation tolerance by inducing Tregs. Tregs have been shown to have significant potential for treating GvHD; in studies by independent researchers, Tregs have proven to produce longer patient survival because they could suppress rejection without reducing an anti-tumor graft versus leukemia effect."The studies show that the administration of RGI-2001 was safe and resulted in increased numbers of Tregs vs. Conventional CD4+ T cells after allogeneic transplantation in some patients, especially in those treated with the mammalian target of rapamycin inhibitor sirolimus as part of their GvHD prophylaxis regimen, commented Dr. Jack Bui. The Phase IIa clinical trial of single-dose RGI-2001 on day 0 in the treatment of 29 patients undergoing allogeneic HCT demonstrated that some patients treated with RGI-2001 had markedly increased the number of Tregs (CD4+CD25+CD127loFoxp3+) within 1 to 3 weeks after HCT. The patients who responded with an increased number of Tregs also had decreased GvHD onset compared with nonresponders. Some of the patients in this subset received sirolimus in addition to the standard of care using calcineurin inhibitors plus methotrexate for immunosuppression after HCT, suggesting potential synergy between sirolimus and RGI-2001 in Treg expansion in vivo. A randomized study is being designed to further evaluate the impact of serial dosing of RGI-2001 on Treg biology and GvHD prevention.
REGiMMUNE Corporation Announces Address Change
Dec 12 16
REGiMMUNE Corporation has moved its business to a new location. The new address is as follows: 35-3 Nihonbashi Hakozaki-cho BRICK GATE 5F Chuou-ku Tokyo 103-0015 Japan. Telephone numbers remain the same.
REGiMMUNE Announces Executive Changes
Jul 1 16
REGiMMMUNE announced that its Board of Directors has appointed Kenzo Kosuda as Chief Executive Officer effective July 1, 2016. Yasuyuki Ishii will assume the role of Executive Chairman on July 1, 2016, and will continue to serve as the Chairman of REGiMMUNE’s Board. Kenzo joined REGiMMUNE in 2013. He most recently served as REGiMMUNE’s executive vice president and CFO/COO. REGiMMMUNE also announced that Yasuyuki Ishii, currently President and CEO, will remain on the board and assume the role of Executive Chairman on June 15. He will devote his time to supporting Kenzo and expanding the applications of reVax technology as both inventor and evangelist. Yasuyuki Ishii has served as independent director of REGiMMMUNE since inception, in 2006 and as CEO from 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|